Kornimate/medical-research-clean huggingface dataset:
treatment for post acute covid-19 syndrome

Conditions: Tinnitus, Subjective

Summary: post-acute covid-19 tinnitus has not been treated successfully. as tinnitus may be related to sars-cov-2 neurological manifestations. this study aims to investigate if the dopamine receptor antagonists can be used effectively treat covid-19 induced tinnitus.

severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is the causative viral pathogen leading to the covid-19 pandemic. in 2022, after three successive waves of the pandemic, the majority of the human population has been exposed to the sars-cov-2 virus. during the two years since the pandemic ensued, multiple reports emerged of patients experiencing covid-19 emergent symptoms lasting longer than 4 weeks since onset. up to 15% of patients recovering from covid-19 experience post-acute covid-19 induced tinnitus . to-date, post-acute covid-19 tinnitus has not been treated successfully. as tinnitus may be related to sars-cov-2 neurological manifestations. this study aims to investigate if the dopamine receptor antagonist pimozide can be used effectively treat covid-19 induced tinnitus.

Eligibility criteria:
inclusion criteria: 1. diagnosed with subjective tinnitus post covid-19 2. tinnitus persists for at least 4 weeks 3. prior history of mild or no tinnitus 4. 18 years or older 5. any gender 6. females of child bearing age must be on contraception exclusion criteria: 1. pregnant 2. patients who participated in any interventional studies in the past 6 months 3. patients with severe hepatic impairment on admission (alanine aminotransferase higher than fivefold the upper limit) 4. patients taking any dopamine receptor antagonists 5. patient having history of hypersensitivity to pimozide 6. patients unable to comply with the study schedule 7. actively using cortiocosteroids
efficacy study of two choices of phototherapy on itching skin diseases

Conditions: Eczema; Psoriasis

Summary: this is a double-blind prospective randomized monocenter study comparing the efficacy of two phototherapy ultraviolet spectra on pruritus (itching) of inflammatory skin diseases. 40 patients per treatment, in total 80 study participants.

in patients with a skin disease and the given indication for a phototherapy with ultraviolet b narrow-band (uvb narrowband, 311nm) with or without ultraviolet a (uva, 320-400 nm), the subjective pruritus levels and clinical severity will be measured before, during and after completion of the 16-week therapy (40 patients per group). patients will be recruited in the department of dermatology of the university hospital zürich in the outpatient clinic. following oral and written consent, pruritus levels will be measured by a visual analogue scale and a new, detailed pruritus score 2 before start of therapy, every 4 weeks after start as well as after completion of the phototherapy. phototherapy is to be administered 3 times per week. the study includes 5 study visits and up to 43 treatment visits that include administration of phototherapy only. a physical examination including clinical scores (psoriasis area and severity index pasi, eczema area and severity index easi, physician's static global assessment psga and dermatology dynamics vector ddv) will be performed at every visit. during the first physical examination the fitzpatrick-skin type of patient will be recorded, the demographics, the body mass index (bmi), diagnosis, past medical history, co-morbidities, concomitant medication and the number of past uva/b treatments.

Eligibility criteria:
inclusion criteria: - pruritic inflammatory diseases such as atopic dermatitis, other types of eczema, psoriasis, prurigo simplex subacuta and others. main inclusion criteria: * pruritus vas score 5 or higher at screening. * dermatological indication for a phototherapy with uvb nb / uva * oral and written informed patient consent exclusion criteria: - patients will be excluded from the study if they fulfill any of the following criteria: 1. foreseeable interruption of the light therapy for more than 14 days, or interruption of the light therapy for more than 14 days during the study 2. heightened photosensitivity for uva or uvb 3. withdrawal of consent to participate 4. concomitant participation in another study or having taken part in another clinical study within the last 30 days.
study of rss0343 tablets in patients with non-cystic fibrosis bronchiectasis

Conditions: Adolescent Asthma

Summary: studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of rss0343 tablets in patients with non-cystic fibrosis bronchiectasis


Eligibility criteria:
inclusion criteria: 1. age 18-75 years old (including boundary values), male and female. 2. female subjects weigh ≥45 kg and male subjects weigh ≥50 kg. 3. hrct shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as ncfb. 4. the expected survival is greater than 12 months. 5. informed consent was signed before the trial. 6. potentially fertile subjects voluntarily take appropriate contraceptive measures. exclusion criteria: 1. patients with pulmonary hypertension or chronic obstructive pulmonary disease (copd) or asthma as determined by the investigators were the primary diagnosis were screened. 2. an active, symptomatic infection caused by respiratory viruses, including covid-19, influenza viruses, etc. 3. have psoriasis or lichen planus. 4. have wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis. 5. have chlorine acne, large common warts, or keratodermatitis. 6. has diabetic foot. 7. have periodontal disease, oral infection, or loose teeth. 8. history of malignant tumor within 5 years prior to screening. 9. screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure. 10. researchers consider any other unstable clinical disease. 11. oral or inhaled antibiotics were received 4 weeks prior to first administration. 12. immunosuppressants were administered 4 weeks before the first dose. 13. received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin. 14. received live attenuated vaccine within 30 days prior to initial administration. 15. participated in clinical trials of any medical device within 3 months prior to screening. 16. active hepatitis b virus infection, active hepatitis c virus infection, or known hiv infection or known syphilis infection. 17. drug abusers. 18. current smoker or former smoker for less than 3 months. 19. suspected allergy to the investigational product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure. 20. pregnant or lactating women. 21. the subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card. 22. the researchers determined that there were other circumstances that were not suitable for participation in this study.
yoga as a supportive therapy for patients with hypertension

Conditions: Hypertension

Summary: the proposed study aims to investigate the feasibility, effectiveness, and perceived benefit of a supportive hatha yoga intervention for patients with hypertension using antihypertensive drugs. patients will be randomized into 3 groups comparing hatha yoga with yoga postures, breathing and relaxation techniques to a hatha yoga intervention without yoga postures (only breathing and relaxation techniques) as well as to a wait list control group.


Eligibility criteria:
inclusion criteria: * essential hypertension * stable antihypertensive medication during the next 6 months exclusion criteria: * pregnancy or breast feeding * simultaneous participation in further clinical intervention trials * regular yoga practice in the past 12 months * serious mental illness (severe depression, severe addiction, psychosis) * manifest coronary heart disease that has been treated in the past 3 months or myocardial infarction, embolism of pulmonary arteries or stroke in the past 3 months * heart failure ≥ state 1 new york heart association (nyha) * peripheral arterial occlusive disease ≥ state 1 * renal insufficiency \> state 2, glomerular filtration rate \< 60 ml/min/1,73m² according to he national kidney foundation (nkf)
clinical implication cmr in ami registry

Conditions: Acute Myocardial Infarction

Summary: 1. to evaluate the clinical implication of cardiac magnetic resonance imaging in patients with acute myocardial infarction 2. to determine factors affecting the 6-month remodeling index assessed by cardiac magnetic resonance imaging

to date, advances in medical treatment and reperfusion therapy led to markedly decreased morbidity and mortality rate in patients with acute myocardial infarction (ami). nevertheless, there is a deterioration of left ventricular systolic function or development of heart failure in 40-50% of surviving patients with ami after the percutaneous coronary intervention (pci), and it is related to infarct size at the index procedure. conventional methods of measuring the infarct size included electrocardiogram, peak cardiac enzyme, and echocardiography, but these do not indicate the exact irreversible tissue damage and only suggest indirect parameters. however, cardiac magnetic resonance imaging (cmr) provides information on infarct size, microvascular obstruction, transmurality, and salvage index, and discriminative function between viable and non-viable myocardium with high spatial resolution. also, magnetic resonance imaging is used as a gold standard for the evaluation of the myocardial remodeling index. however, it is not well known in which patients occur adverse remodeling for the myocardium and in which patients occur reverse remodeling. therefore, the investigators sought to evaluate the clinical implication of cmr and to determine factors affecting the 6-month remodeling index assessed by cardiac magnetic resonance imaging through the current registry.

Eligibility criteria:
inclusion criteria: * subjects diagnosed as type 1 myocardial infarction the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia. exclusion criteria: * patients who cannot perform cardiac magnetic resonance imaging * target vessel is not suitable for coronary intervention

Keywords: percutaneous coronary intervention acute myocardial infarction cardiac magnetic resonance imaging
mechanism of action of vichy catalan water

Conditions: Cardiovascular Diseases

Summary: water consumption is essential to maintain hydration and good health. sodium-bicarbonated mineral waters are reported to have beneficial digestive and hypocholesterolemic properties. the aim of this study was to investigate the effects of the consumption of a sodium-bicarbonated mineral water (bw) with or without a meal, compared to a low mineral content water as a control water (cw), on postprandial serum triacylglycerols (tag), cholecystokinin (cck), and gallbladder volume.


Eligibility criteria:
inclusion criteria: * adult (\>18 and \<40 years) * bmi \>18 and \<30 kg/m2 exclusion criteria: * age \ 40 years * tag \> 250 mg/dl (2.82 mmol/l) * being a usual consumer of carbonic mineral water * obesity * diabetes * hypertension or digestive, liver and renal disease * biliary obstruction * eating disorders * being under medication that could affect lipid metabolism * consumption of functional foods that could affect lipid metabolism (food containing n-3 fatty acids or phytosterols)

Keywords: cardiovascular risk cholecystokinin gallbladder emptying lipid absorption postprandial triacylglycerols sodium-bicarbonated mineral water
exercise weight loss

Conditions: Overweight and Obesity

Summary: the overall aim of this study is to investigate the effects of home-based resistance exercise programme on changes in body composition and strength during weight loss, in people living with obesity or overweight.


Eligibility criteria:
inclusion criteria: * obesity or overweight (bmi ≥ 25kg/m2). * passing the physical activity readiness questionnaire (par-q+) exclusion criteria: * currently take part in more than 1.5 hours of structured exercise per week. * having recently (\<6 months) taken part in any resistance exercise training, taking any medications known to affect weight loss. * actively engaged in a weight loss programme, having lost more than 2kg weight in the last 6 months. * any other reason which would limit ability to perform the exercises and outcome measurements safely.
urinary artificial sphincter in children

Conditions: Neurogenic Bladder; Bladder Dysfunction; Spina Bifida; Child, Only

Summary: retrospective monocentric study of the outcomes of patients with neurogenic bladder, who had a urinary artificial sphincter before the age of 18 years old. hypothesis: what was the impact of the urinary artificial sphincter on the global management of the patient.

the management of patients with neurogenic bladder is complex. several patients have been operated multiple times. surgical procedures such as mitrofanoff's, bladder neck surgery, bladder augmentation and urinary artificial sphincter, are common. the investigators want to analyse the participants data, that led to indication of an urinary artificial sphincter, and its outcomes.

Eligibility criteria:
inclusion criteria: * patients who were younger than 18 years old when they had an urinary artificial sphincter exclusion criteria: * patients who were 18 years old or older when they had an urinary artificial sphincter

Keywords: urinary artificial sphincter neurogenic bladder children outcomes retrospective study
multivessel talent

Conditions: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Heart Diseases; Cardiovascular Diseases; Arterial Occlusive Diseases; Vascular Diseases

Summary: multivessel talent is a prospective, randomized, multi-center study comparing clinical outcomes between supraflex cruz and synergy in approximately 1550 patients with de-novo three vessel disease undergoing percutaneous coronary intervention (pci). patients will be treated according to "state of art pci"; not only treatment strategies based on the latest esc guideline, such as syntax score ii recommendation, heart team discussion, post-procedure intravascular imaging optimization, cholesterol reduction by statin or pcsk-9 inhibitor, but also exploratory treatment strategies based on the latest evidence, such as physiological assessment using quantitative flow ratio and prasugrel monotherapy following 1-month dual antiplatelet therapy after pci.


Eligibility criteria:
inclusion criteria: 1. male or female patients' ≥18 years. 2. at least 1 stenosis (angiographic, visually determined de novo lesions with ≥50% ds) in all 3 major epicardial territories (lad and/or side branch, lcx and/or side branch, rca and/or side branch) supplying viable myocardium without left main involvement. 3. the vessel should have a reference vessel diameter ranging from ≥2.25 mm to ≤4.50 mm (no limitation on the number of treated lesions, vessels, or lesion length). 4. patients with chronic coronary syndrome or stabilized acute coronary syndromes. 5. all anatomical syntax scores are eligible for initial screening with the syntax score ii, provided that the syntax score ii recommends equipoise risk (pci or cabg) or pci only. 6. patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the ethical committee and is willing to comply with all protocol-required evaluations. 7. agree with conditional longer follow up from 2 to 5 years with one phone contact yearly. exclusion criteria: 1. under the age of 18. 2. unable to give informed consent. 3. patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice). 4. known contraindication to medications such as aspirin, heparin, bivalirudin, prasugrel and ticagrelor. 5. prior pci or prior cabg. 6. ongoing st-elevation myocardial infarction (stemi). 7. cardiogenic shock is also an exclusion criteria. 8. concurrent medical condition with a life expectancy of less than 2 years. 9. currently participating in another trial and not yet at its primary endpoint. 10. patient with both ostial lad and ostial lcx stenosis, or left main stenosis. 11. previous intracranial haemorrhage.

Keywords: multi-vessel coronary artery disease revascularization quantitative flow ratio fractional flow reserve instant wave-free ratio syntax score prasugrel monotherapy ultra-thin strut sirolimus-eluting coronary stent
can quantitative ultrasound be used for the evaluation of bone health in adolescents and adults with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: measurement of bone density of cystic fibrosis patients with two techniques and correlation to serum bone parameters, use of steroids, lung function and nutritional status.

measurement of bone density of cystic fibrosis patients with two techniques and correlation to serum bone parameters, use of steroids, lung function and nutritional status.

Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis exclusion criteria: -
resting heart rate in chronic obstructive pulmonary disease

Conditions: Pulmonary Rehabilitation; Exercise; COPD; Resting Heart Rate

Summary: 110 copd patients who were participated in the pr program were included in the study. resting heart rate , pulmonary functions, functional capacity, perception of dyspnea, quality of life and psychological symptoms compared before and after pr.

in many studies, it has been reported that baroreceptor activity and heart rate variability decrease and resting heart rate (rhr) increases in copd patients due to changes in cardiac autonomic function. among the recommendations regarding pulmonary rehabilitation (pr) and exercise training in copd patients, approaches such as including practices targeting rhr and developing implementation strategies that improve the cardiovascular system are recommended. the primary aim of our study is to examine the effect of comprehensive exercise training consisting of breathing, aerobic and strengthening exercises on rhr in copd patients, and secondarily to determine the factors that affect rhr change after pr in copd patients. 110 copd patients who were participated in the pr program were included in our retrospective study. resting heart rate , pulmonary functions, functional capacity, perception of dyspnea, quality of life and psychological symptoms compared before and after pr.

Eligibility criteria:
inclusion criteria: * patients diagnosed with copd according to gold and completed the 2-day / 8-week pr program exclusion criteria: * with cardiovascular disease * with additional diseases such as diabetes * receiving medical treatment that affects the autonomic nervous system * patients receiving long-term oxygen therapy

Keywords: resting heart rate copd exercise pulmonary rehabilitation
antiretroviral therapy and inflammatory and coagulation biomarkers: imacs study

Conditions: HIV (Human Immunodeficiency Virus); AIDS (Acquired Immune Deficiency Syndrome); Tuberculosis; Non-communicable Diseases (NCD)

Summary: the aim of this study is to develop and follow a cohort of human immunodeficiency virus (hiv)-infected adults who are starting hiv drugs at health facilities in kenya. blood and urine samples will be collected from all participants in order to establish a sample bank of samples in order to further the understanding of the levels of inﬂammatory biomarkers and coagulation biomarkers in african patients and the effect of taking hiv drugs on these biomarkers. this study will enroll and follow 685 men and women who are starting hiv drugs and collect blood and urine specimens from them at 4 study visits. these samples will be frozen and stored for future testing related to inﬂammatory and coagulation biomarkers.

biomarkers have been investigated as predictors of hiv disease progression, i.e. development of acquired immunodeficiency syndrome (aids) deﬁning diagnoses or death. there are limited data on the levels of these biomarkers among hiv-infected individuals in sub saharan africa and on the effect of antiretroviral therapy (art) initiation on these levels. in addition, further work is needed to examine the association between such markers and various complications associated with hiv as well as mortality in sub saharan africa. the overall aim of this study is to develop a cohort of hiv-infected adults who are initiating art at health facilities in kenya and to establish a sample bank of plasma and urine samples in order to further the understanding of the levels of inﬂammatory biomarkers (ibm) and coagulation biomarkers (cbm) in african patients and the effect of art initiation on these biomarkers. the study objectives are as follows: * to recruit, establish and follow a cohort of hiv-infected individuals who are eligible for initiation of art through 12 months * to obtain blood and urine samples on all cohort participants at baseline, months 2, 6, and 12 for future hiv and related research * to describe the demographic and disease characteristics of cohort participants and associations with various biomarkers

Eligibility criteria:
inclusion criteria: * men and women at least 18 years of age * known to be hiv positive * art-naïve (with exception of prior exposure to single dose nevirapine in women) * documented art eligibility based on cd4+ cell count and/or who staging * willing to provide locator information and to adhere to study procedures. * no intention of permanently moving away from area for coming 12 months exclusion criteria: * individuals who do not meet the inclusion criteria outlined above * women who are currently pregnant * any condition which in the opinion of the investigators would interfere with participation in the study

Keywords: antiretroviral therapy (art) biomarkers nyanza province kenya
the purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * participant has clinically confirmed diagnosis of active ad for at least a 6-months. * participant has chronic pruritus related to ad for at least 3 months . * participant has an overall bsa (excluding palms, soles, scalp, genitals, and folds) affected by ad of 1%-20% on day 1. * participant has an iga score of at least 2 on day 1. * participant has a single pp-nrs score ≥ 4 in the 24-hour period prior to the screening visit. * willingness to avoid pregnancy or fathering children. * participant must be willing to comply with all study procedures and restrictions including discontinuation of all current therapies for ad and pruritus (unless otherwise specified), and must be available for the duration of the study. exclusion criteria: * female participnat who is breastfeeding, pregnant, or planning to become pregnant during the study. participant had significant flares or unstable course in ad. * participant has clinically infected ad or has used antibiotics (systemic or topical) for their infected ad within 2 weeks prior to the run-in period. * participant has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments. * participant has any clinically significant medical condition or physical/laboratory/vital sign abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. * participant has received treatment with jak inhibitors (systemic or topical) within 4 weeks prior to the run-in period. * participant is unlikely, in the opinion of the investigator, to be compliant with study procedures and requirements.

Keywords: ruxolitinib itch chronic pruritus